These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23105224)

  • 21. The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis.
    Couser WG; Johnson RJ; Young BA; Yeh CG; Toth CA; Rudolph AR
    J Am Soc Nephrol; 1995 May; 5(11):1888-94. PubMed ID: 7620086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroprotective effects of the SCR1-3 functional domain of CR1 on acute cerebral ischemia and reperfusion injury in rats.
    Yang S; Wang X; Zhang X; Lu Y; Wang Z
    Neurol Res; 2013 Nov; 35(9):976-83. PubMed ID: 23815859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complement receptor 1 (CR1, CD35) association with susceptibility to leprosy.
    Kretzschmar GC; Oliveira LC; Nisihara RM; Velavan TP; Stinghen ST; Stahlke ERS; Petzl-Erler ML; Messias-Reason IJT; Boldt ABW
    PLoS Negl Trop Dis; 2018 Aug; 12(8):e0006705. PubMed ID: 30092084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble complement receptor type 1 inhibits the complement pathway and prevents contractile failure in the postischemic heart. Evidence that complement activation is required for neutrophil-mediated reperfusion injury.
    Shandelya SM; Kuppusamy P; Herskowitz A; Weisfeldt ML; Zweier JL
    Circulation; 1993 Dec; 88(6):2812-26. PubMed ID: 8252695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective inhibition of the alternative complement pathway by sCR1[desLHR-A] protects the rabbit isolated heart from human complement-mediated damage.
    Gralinski MR; Wiater BC; Assenmacher AN; Lucchesi BR
    Immunopharmacology; 1996 Sep; 34(2-3):79-88. PubMed ID: 8886851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced complement receptor 1 (CR1, CD35) transcription in systemic lupus erythematosus.
    Arora V; Verma J; Dutta R; Marwah V; Kumar A; Das N
    Mol Immunol; 2004 Jun; 41(4):449-56. PubMed ID: 15163541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Soluble form of complement C3b/C4b receptor (CR1) results from a proteolytic cleavage in the C-terminal region of CR1 transmembrane domain.
    Hamer I; Paccaud JP; Belin D; Maeder C; Carpentier JL
    Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):183-90. PubMed ID: 9405292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Soluble complement receptor type 1 inhibited the systemic organ injury caused by acid instillation into a lung.
    Nishizawa H; Yamada H; Miyazaki H; Ohara M; Kaneko K; Yamakawa T; Wiener-Kronish J; Kudoh I
    Anesthesiology; 1996 Nov; 85(5):1120-8. PubMed ID: 8916830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis.
    Weisman HF; Bartow T; Leppo MK; Marsh HC; Carson GR; Concino MF; Boyle MP; Roux KH; Weisfeldt ML; Fearon DT
    Science; 1990 Jul; 249(4965):146-51. PubMed ID: 2371562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble complement receptor type 1 in serum and cerebrospinal fluid of patients with Guillain-Barré syndrome and multiple sclerosis.
    Vedeler CA; Matre R; Sadallah S; Schifferli J
    J Neuroimmunol; 1996 Jun; 67(1):17-20. PubMed ID: 8707926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of soluble complement receptor-1 on neutrophil accumulation after traumatic brain injury in rats.
    Kaczorowski SL; Schiding JK; Toth CA; Kochanek PM
    J Cereb Blood Flow Metab; 1995 Sep; 15(5):860-4. PubMed ID: 7673379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic inhibition of the complement system. Y2K update.
    Asghar SS; Pasch MC
    Front Biosci; 2000 Sep; 5():E63-81. PubMed ID: 10966868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elastase and metalloproteinase activities regulate soluble complement receptor 1 release.
    Sadallah S; Hess C; Miot S; Spertini O; Lutz H; Schifferli JA
    Eur J Immunol; 1999 Nov; 29(11):3754-61. PubMed ID: 10556832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic and structural polymorphism of complement receptor 1 in normal Indian subjects.
    Katyal M; Sivasankar B; Ayub S; Das N
    Immunol Lett; 2003 Oct; 89(2-3):93-8. PubMed ID: 14556965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of the complement cascade by soluble complement receptor type 1. Protective effect in experimental liver ischemia and reperfusion.
    Chávez-Cartaya RE; DeSola GP; Wright L; Jamieson NV; White DJ
    Transplantation; 1995 Apr; 59(7):1047-52. PubMed ID: 7709442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble complement receptor 1 inhibits both complement and granulocyte activation during ex vivo hemodialysis.
    Himmelfarb J; McMonagle E; Holbrook D; Toth C
    J Lab Clin Med; 1995 Oct; 126(4):392-400. PubMed ID: 7561449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of soluble complement receptor 1 (sCR1) and human thyroid antibodies on the course of experimental autoimmune thyroiditis in rats.
    Metcalfe RA; McIntosh RS; Morgan BP; Levin JL; Weetman AP
    Autoimmunity; 1996; 23(1):1-8. PubMed ID: 8871757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of complement inhibition with soluble complement receptor 1 on pig allotransplant lung function.
    Pierre AF; Xavier AM; Liu M; Cassivi SD; Lindsay TF; Marsh HC; Slutsky AS; Keshavjee SH
    Transplantation; 1998 Sep; 66(6):723-32. PubMed ID: 9771835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of complement inhibition with soluble complement receptor-1 on vascular injury and inflammation during renal allograft rejection in the rat.
    Pratt JR; Hibbs MJ; Laver AJ; Smith RA; Sacks SH
    Am J Pathol; 1996 Dec; 149(6):2055-66. PubMed ID: 8952538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor.
    Makrides SC; Nygren PA; Andrews B; Ford PJ; Evans KS; Hayman EG; Adari H; Uhlén M; Toth CA
    J Pharmacol Exp Ther; 1996 Apr; 277(1):534-42. PubMed ID: 8613964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.